NCT00205647

Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis

A Phase II Multicenter Efficacy, Safety and Dose-Effect Study of the Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable, Chronic Bronchitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (planned)
• Sponsor: Wake Forest University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randonmized, masked, placebo-controlled parallel group, clinical trial to evaluate the effects of three different doses of N-acetyl L-cysteine (NAC) and placebo on patient safety and on physical and transport properties of expectorated sputum. Patient sumptoms, quality of life and exacerbation will also be followed as well as pulmonary function testing and functional exercise capacity. We hypothesized that a prolongeed course of oral NAC favorably affects the morbidity of chronic bronchitis, particularly the incidence of acute exacerbations.

Conditions

• Chronic Bronchitis

Interventions

Type	Name	Description
DRUG	Oral N-acetycystein (NAC)

Timeline

• Start date: 1997-01-01
• Completion: 2000-03-01
• First posted: 2005-09-20
• Last updated: 2017-11-06

Locations

1 site across 1 country: United States